Probatebeta
Target

PDE3A

cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

As of the edition of 20 October 2026, PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A, UniProt Q14432) has 14 drugs tested at it and 12 companies on the list, 2 on route A and 4 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q14432
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
9
Disease areas
Heart and blood vessels; Nervous system; Lungs and airways; Nutrition and metabolism; Urinary and reproductive; Immune system; Pregnancy and women's health; Inherited and neonatal
Registered trials of its drugs
311

Drugs at this target

StatusCount
Marketed11
Active1
Went quiet1
Stopped1
Total14
DrugStatusFurthest phaseUS protection
CilostazolMarketedPhase 4none listed
Theophylline anhydrousMarketedPhase 4none listed
LevosimendanMarketedPhase 4none listed
MilrinoneMarketedPhase 3none listed
EnsifentrineMarketedPhase 3Ends 2031
IbudilastMarketedPhase 3none listed
AnagrelideMarketedPhase 4none listed
EnoximoneMarketedPhase 4none listed
BAY2666605StoppedPhase 1none listed
K-134Went quietPhase 2none listed
TNX-103ActivePhase 3none listed
DyphyllineMarketedNo phase statednone listed

12 of 14 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A2
Route B4
Engaged1
Undetermined5
Total on the list12
Three companies on route A or B, with the route only
CompanyRoute
OtsukaRoute B
Libbs Farmacêutica LTDARoute B
TakedaRoute B

The other 9 companies at PDE3A

In the product

12 companies in all; 9 are not named here, and no score is.

See the 12 companies at PDE3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in heart and blood vessels

Companies holding approvals at PDE3A